Senior Managed Care Pharmacist Health First Health Plans Melbourne, Florida
Biosimilars are considered a fundamental pillar to containing drug spend in today’s health care systems. Unfortunately, biosimilars are having a difficult time penetrating the market and face many barriers to their acceptance among both providers and payers. These barriers often delay the acceptance of biosimilars as legitimate treatment options and impede the uptake of biosimilar utilization for years after their approval. As managed care pharmacists, it is important that we are knowledgeable and prepared to address all the common barriers to biosimilar utilization so that we can promote cost effective evidence-based medicine.
This session will provide the diverse perspectives of pharmacists throughout one IDN, their coordinated efforts to address barriers to biosimilar utilization both within the integrated delivery network (IDN) and with third-party physician offices, real-world evidence used to support biosimilar use, and the IDN’s experience as it has adopted a “biosimilar first” culture.
Learning Objectives: :
At the completion of this activity, participants should be able to:
Recognize barriers to the utilization of biosimilars.
Explain current evidence supporting the use of biosimilars in different patient populations.
Describe interventions used to promote the use of biosimilars at different health care settings.
Discuss the experience and outcomes achieved of one IDN’s efforts to promote biosimilar utilization.